Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that results from a clinical evaluation of its lead program in gout, NU1618, and pre-clinical data describing the mechanism of action for the tranilast component of NU1618, have been accepted for presentation at the 2010 American College of Rheumatology/Association of Rheumatology Health Professionals (ACP/ARHP) Annual Scientific Meeting, to be held in Atlanta, GA, November 6-11...
More...
More...